Minerva Neurosciences Inc NERV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia
-
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
-
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
-
Minerva Shares Soar on $200 Million Financing for Schizophrenia Drug Trial
Trading Information
- Previous Close Price
- $2.20
- Day Range
- $2.20–2.34
- 52-Week Range
- $2.18–8.80
- Bid/Ask
- $2.24 / $2.50
- Shares Outstanding
- 47.75M
- Market Cap
- $106.48M
- Volume/Avg
- 239,277 / 179,316
Key Statistics
- Price/Earnings (Normalized)
- 1.51
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 7
Valuation
|
Metric
|
NERV
|
|---|---|
Price/Earnings (Normalized) | 1.51 |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
NERV
Financial Strength
|
Metric
|
NERV
|
|---|---|
Quick Ratio | 19.02 |
Current Ratio | 20.14 |
Interest Coverage | — |
Quick Ratio
NERV
Profitability
|
Metric
|
NERV
|
|---|---|
Return on Assets (Normalized) | −553.59% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
NERV
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!b$D$H@ | LOCK|NSBQ | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!Nh^rj | LOCK|^!&lC | $84B | |||
| Moderna Inc
MRNA
| LOCK|#SrVc>q | LOCK|t@! | $83B | |||
| argenx SE ADR
ARGX
| LOCK|?^z>S< | LOCK|$xF | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|xPHCTQ | LOCK|cQ? | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|m^!tHFH | LOCK|$Fg>@ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|K>NRV!! | LOCK|kh?Xf | $29B | |||
| Incyte Corp
INCY
| LOCK|%x^#N>> | LOCK|#x | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|@MFbRq% | LOCK|v> | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|D<TQWV | LOCK|?! | $14B |
United States